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SUMMARY
Background: Epidemiological and animal studies demonstrated a link between gastric cancer (GC) or mucosal as-
sociated lymphoid tissue (MALT) lymphoma and chronic infection with Helicobacter pylori (H. pylori). The exact
mechanism responsible for the development of GC and MALT-lymphoma in H. pylori-infected patients still rema-
ins obscure. This report is designed to overview the molecular biology, especially the gene expression and histoche-
mical manifestation of gastrin and other growth factors such as transforming growth factor alpha (TGFα) and he-
patocyte growth factor (HGF) in the GC before and after eradication of H. pylori. Furthermore, gene expression of
cyclooxygenase-1 (COX-1) and COX-2 and apoptosis-related proteins such as Bax and Bcl-2 are discussed.
Material and methods: The findings originate from two series of patients; Series I involving 337 GC patients and
400 age- and gender-matched controls and series 2 including 20 MALT-lymphoma patients and 40 matched
controls.
Results: An overall H.pylori-seropositivity reached about 80% in GC and about 90% in MALT-lymphoma, si-
gnificantly higher than in non-cancer controls (60%). The prevalence of CagA-positive strains was about twice
as high (about 70%) in GC and MALT-lymphomas as in sex- and age-matched controls. Expression of gastrin
was detected in antrum of all tested patients but also in majority (90%) of GCs and MALT-lymphomas tumor
tissue. HGF and TGFα were expressed more frequently in GC tissue than in normal fundic mucosa. COX-1
was similarly expressed in GC and MALT as in intact mucosa, while COX-2 mRNA was detected only in tu-
mor tissue, being attenuated by H.pylori eradication in GC and abolished by this therapy in MALT-lymphoma.
The plasma levels of α-amidated gastrin in GC and MALT were several folds higher than in controls. Gene
expression of bcl-2 was detected in all, while bax – only in about 50% of GC samples.
Conclusions: Infection with H. pylori, especially that expressing CagA-positivity, is primum movens in develo-
ping GC and MALT-lymphoma and the upregulation of growth factors, particularly of gastrin, and COX-2 and
dysregulation of the Bax/Bcl-2 system seem to contribute to gastric cancerogenesis.
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BACKGROUND
Gastric cancer (GC) and MALT-lymphoma, the
most common malignancies in the digestive system
[1,2], are linked to H. pylori infection and develop
almost exclusively in the stomach with atrophic ga-
stritis and intestinal metaplasia or dysplasia caused
by this infection (Fig. 1). The discovery of this in-
fection is considered as one of the most important
advances in gastroenterology at the turn of the 3rd
millennium [3] and H. pylori has been classified in
1994 by the International Association for Research
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against Cancer (IARC) as a carcinogen type 1 for
GC [4] and the cause of MALT-lymphoma [5].
H. pylori is probably the most common bacterial in-
fection with a world-wide prevalence approximating
50% [6] (Fig. 2). Epidemiological reports [7,8] sugge-
sted and animal studies [9,10] confirmed that the
chronic infection with H. pylori is an important risk
factor for the development of GC. Infection with H.
pylori alters many gastric factors that contribute to
the pathogenesis of GC such as induction of atrophic
gastritis with intestinal metaplasia and dysplasia, pre-
dicted by Correa et al, long before the discovery of
H. pylori [11,12]. With the recognition of crucial role
of H. pylori and gastrin upregulation as missing steps
in cancerogenesis the so called Correa’s cascade has
to be accordingly modified (Fig. 3). This does not re-
fute the significance of genetic component including
polymorphism of interleukin (IL)-1 or rare hereditary
diffuse gastric cancer [13] as well as the contribution
of various carcinogenic factors including N-nitroso-
-compounds, reactive oxygen species, decreased vi-
tamin C contents in gastric juice, increased epithelial
cell turnover and others. [13–20].
The 1st or pre-initiation step in gastric cancero-
genesis results from the action of various environ-
mental carcinogens including prolong exposure to
microbial or viruses, contact with noxious chemi-
cals or excessive radiation of gastric mucosal cells
result in acquired (environmental) DNA damage.
They cause the changes in the stability of the DNA
and whole genome. At this step, the prevention of
the exposition to the microbes or viruses, the re-
duction or avoidance of the contact with chemical
such as e.g. smoking, decrease in the exposition to
sun and increased intake of foods containing sca-
venges of reactive oxygen or nitrogen species
(ROS) such as vegetables and fruits or supplemen-
tation with anti-oxidant vitamins A, C, D and E are
the only ways of preventing further DNA damage
and helping the recovery of the genes coding the
enzymes repairing the existing DNA damage.
RESULTS AND DISCUSSION
The H. pylori IgG and CagA seroprevalence in
gastric cancer patients, the initiation step of
cancerogenesis
As described by Correa et al [21], long before the di-
scovery of H. pylori, the development of GC is a mul-
tistep process in which environmental and genetic
factors determine the transformation of normal gastric
epithelial cells into metaplastic, dysplastic and finally
malignant cells (see Fig. 3). The sequence of events
from normal mucosa to atrophic gastritis with intesti-
nal metaplasia (without or with gastric polyps) and fi-
Figure 1. Sequence of histological and endoscopic events in H. pylori infected stomach with accompanying transformation of chronic atrophic
gastritis to chronic active gastritis with polyp, intestinal metaplasia and dysplasia to cancer. The Burma’s ‘pagoda’ illustrates the decreasing
frequencies of chronic active gastrirtis through gastric atrophy, metaplasia, dysplasia and finally gastric cancer.
nally to GC or MALT-lymphoma, has been verified
both endoscopically and histologically, but each step
may take several years to develop through the initia-
tion (step 2), progression (step 3) and spread (step 4)
of cancer. In case of the H. pylori infection the initia-
tion may occur even at younger age such as in Japan
where the risk of GC expressed in term of odds ratio
(OR) below 40 years reaches about 13 (95% Cl:
5.3–36.0). There are conflicting data concerning the
significance of the association of the GC with the H.
pylori CagA status in Japan but, in contrast, an incre-
ased association of GC with the H. pylori CagA geno-
type was found in young Italian patients [23].
The most important for the initiation step of can-
cerogenesis (step 2) is the entrance of the cell into
the mutation pathway, especially concerning the
genes coding enzymes repairing DNA and genes
suppressors of the neoplastic transformation.
Among the more important events of this initiation
step are; a) the activation of protooncogens such as
K-ras, stimulating cell proliferation rather than their
differentiation, b) the expression and release of ga-
strin as well as other growth factors by precancero-
us cells, c) the mutation of the suppressor genes
such as p53, d) the dysregulation of apoptotic genes
leading to the enhancement of activity of antiapop-
totic gene such as bcl-2 with the decline of pro-
apoptotic genes such as bax with inhibition of
apoptosis and e) the dysregulation of the DNA re-
pair genes. These cells with mutation of certain ge-
nes are still stimulated to grow and proliferate by
the same growth factors as normal cells i. e. gastrin
and other growth factors (HGF and TGFα), acting
by separate gastrin or growth factor receptors that
can be identified using specific primers and RT-PCR
or Western blot. Our studies using these techniques
clearly demonstrated the existence of gastrin and its
gastrin-receptors so called CCKB-R and EGF-recep-
tors (EGF-R) that transduce the action of these
growth factors (produced in excessive amounts)
through intracellular signaling enzymes starting with
receptor-bound tyrosine kinase responsible for the
phosphorylation of regulatory proteins of the activa-
tion of cell division, proliferation and tumor growth.
Our Polish study presented in abstract form [24] inc-
luded 337 GC patients aging from 21 to 80 yrs with
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Figure 2. World distribution of H. pylori infection and its gastric consequences from common chronic gastritis (100% infected) to cancer (about 2%).
1095
Konturek PC et al – Cancerogenesis in Helicobacter pylori infected stomach…
median age 59.4 yrs and 337 sex- and age-
-randomly selected controls, the overall H. pylori se-
ropositivity was significantly higher (91%) than in
controls (78%), while CagA seropositivity was rough-
ly twice as high in GCs (59%) as in controls (25%).
This difference in H. pylori IgG and CagA prevalence
was observed at almost all tested age groups (Fig. 4).
A summary OR (SOR) for H. pylori IgG in GC was
about 2.6 reaching, like in Italian study, the highest
value of 8.09 at the age 40–49. SOR for CagA avera-
ged 4.1 supporting the notion that the risk of GC in
H. pylori patients was markedly increased for infec-
tion with those bacteria that were CagA positive.
The overall percentage of patients with positive H.
pylori IgG, CagA and plasma gastrin, IL-1 and lumi-
nal pH above the cut-off values in GC and controls
are shown on Fig. 5.
Role of growth factors in the initiation and pro-
motion of gastric cancer and possible therapeutic
application of anti-growth factors in the control of
tumor cell growth
During the last decade, extensive studies have be-
en performed to define the molecular mechanism
underlying the progression from normal to mali-
gnant cells though the underlying molecular pa-
thomechanism of GC and the exact role of H. py-
lori in carcinogenesis remain undetermined. The-
re is an accumulating evidence that the transfor-
mation of the normal H. pylori infected gastric
mucosal cells into the malignant cells and the de-
velopment of GC require the action of mucosal
growth promoting factors such as gastrin, HGF
Figure 3. Modified ‘Correa’s cascade’ including the role of H. pylori,
gastrin and major oncogens (on left). Gastric tumors arise
from various cells but most frequent adenocarcinoma
originates from the neck mucous cells while MALT
lymphoma – from lymphocytes in deeper wall layer.
Figure 4. H. pylori seropositivity (upper panel) and CagA (lower panel)
in GC patients and healthy controls at various age groups.
Figure 5. The overall percentage of H. pylori and CagA seropositivity,
plasma gastrin, IL-1β, and luminal pH values above the cut-
off points (calculated with ROC) in GC patients and healthy
controls.
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and TGFα [8–20, 24–26]. The implication of α-
-amidated gastrin G-17 and G-34, as measured
by radioimmunoassay, was reported by our group
two years ago [19] using smaller number of pa-
tients, but now with 337 GC patients and 337
sex-, age-matched controls, we confirmed that
mean values of plasma gastrin in GCs was signifi-
cantly higher than that in controls. The area un-
der the Receiving Operator Characteristics (ROC)
curve was calculated to measure the discrimina-
tion power of various biomarkers such as H. pylo-
ri IgG, CagA, gastrin, IL-1α and intragastric pH
showed that the best cut-off point was then calcu-
lated from this ROC curve was the plasma gastrin
level above 38.9 pM, the intragastric acidity with
pH above 4.50 and plasma IL-1α above 4.0. The
SOR reached the highest value for gastrin in GCs,
being about 10, reaching the peak value of about
15 at age 30–39 and for intragastric pH above 4.5
attaining about 8.0 (see Fig. 5). This study reinfor-
ced our notion that gastrin is the major factor im-
plicated in H. pylori -related gastric carcinogene-
sis and that the measurement of plasma gastrin
and intragastric pH in H. pylori infected patients
provides the strongest discriminative diagnosis of
GC. Our findings may have practical implication
in screening cancer at earlier stage by using the
approach similar to that of PSA (prostate specific
antigen) in detection of prostate cancer. In case of
GC simple measuring plasma gastrin, and gastric
hypochlorhydria (by determination of plasma
pepsinogen level which reflects quite well the ga-
stric secretory and indirectly the atrophy status) in
H. pylori seropositive may be useful in screening
the GC at the preliminary stage. Further nation-
-wide study using these determination may prove
usuful in detecting the precancerous stage or ga-
stric malignancy.
There is also an evidence linking the upregulation
of HGF, normally present in the gastric mucosa, to
the development and progression of various epi-
thelial and nonepithelial tumours [20,26–30].
Another mitogenic peptides, EGF and TGFα, that
are also biosynthesised in the gastric mucosa,
especially following its damage by H. pylori, elicit
their biological action through interaction with
cell-surface epidermal growth factor receptor
(EGF-R) by activating its tyrosine kinase activity
[31]. This interaction of growth factors also results
in the induction of nuclear oncogenes such as c-
-myc, c-jun and c-fos to exert tumor cell growth-
-stimulating effect [32]. Different cancer cell lines
co-express EGF and TGFα and EGF-R, suggesting
that EGF and TGFα may also be implicated in the
carcinogenesis, acting as autocrine growth factors
[33]. Gene expression of HGF and TGFα was fo-
und to be increased in gastric mucosa colonized
by H. pylori, reinforcing a possible link between
these growth factors and H. pylori-associated ga-
stritis and gastric carcinogenesis [18,24,33,34]. Se-
rum TGFα was previously found to be elevated in
GC patients and over-expression of this peptide
was associated with an advanced stage of the can-
cer disease and poor prognosis [26]. It was sugge-
sted to be an useful marker of GC for predicting
the progress of the disease and follow-up after sur-
gery.
Among the growth factors, gastrin appears to be
the most important gastrointestinal hormone invo-
lved in the stimulation of gastric acid secretion via
activating the enterochromaffin-like (ECL)-cells
and releasing histamine and in stimulating epithe-
lial cell proliferation in the gastrointestinal tract,
especially in the fundic and colonic mucosa [35].
In vitro studies have shown that gastrin stimulates
the proliferation of gastric cancer cell lines thro-
ugh the induction of specific mitogen activated
protein kinase [36]. Gastrin is mainly synthesized
in antroduodenal G-cells but there is also an evi-
dence that gastrin, especially α-amidated gastrin,
may be produced in extra-antroduodenal areas,
such as in some solid tumours originating from tis-
sue, which normally express only negligible amo-
unt of gastrin, including pancreas, liver or bron-
chi, which embriologically originate from the sa-
me endoderm tube [37–39]. Chronic infection
with H. pylori in GC patients has been shown to
elevate the plasma gastrin level and to enhance
the release of this hormone into the gastric lu-
men, where it may stimulate the growth of H. py-
lori and release of α-methyl-histamine that in turn
activate the G-cells and cancer cells to produce
more gastrin stimulating the growth of tumor
cells. We showed that H. pylori eradication in GC
patients shortly before the surgery was followed
by a marked and immediate fall in plasma gastrin
level, gastric luminal gastrin content and cancer
tissue gastrin level (Fig. 6).
Treatment of growth factors–dependent gastric
cancer
As examined in vitro isolated gastric mucous cells,
we found that gastrin added to cell culture in com-
bination with other growth factors (TGFα, HGF,
EGF) induced by the H. pylori infection and/or mu-
tated and hyperactive K-ras, causes an overexpres-
sion of p53 and this was followed by the phospho-
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rylation and activation of MAP-kinases resulting in
the activation of cell division and tumor growth are
depicted on the Fig. 7.
In humans at this step of gastric carcinogenesis, the
therapeutic approach should include first of all the
eradication of H. pylori to reduce the production
of major growth promoting factor of malignat cells
such as gastrin. It may be worthwhile to mention
that extensive program of H. pylori eradication as
well as prolonged treatment of gastro-esophageal
reflux with proton pump inhibitors (PPI) such as
omeprazole without eradication of H. pylori not
only results in the decline in the H. pylori prevalen-
ce but also ‘shifts’ the usual GC location in the di-
stal stomach to its proximal part (body and cardia).
This has been explained by the ascension of the
bacteria (in PPI treated patients) from antrum to-
wards the esophageo-gastric junction through the
induction of atrophic gastritis in the corpus and
cardia of the stomach [40].
Recently, the attempts have been made to neutra-
lize gastrin produced by malignant cells with endo-
genously induced gastrin-neutralization antibodies
in various gastric and colorectal cancers. These an-
tibodies are produced by challenging body’s im-
munological system with the complex of gastrin-17
(G-17) with diphteria toxin (G17DT). Such gastrin
neutralizing antibody raised by immunization with
G17DT, called gastrimmune (Afton, USA), has be-
en tried with some success in prolonging the life of
patients with gastric and colorectal cancers but the-
se antibodies are capable of neutralizing only α-
-amidated G-17 (Fig. 8), but colorectal cancers
produce mainly glycine extended gastrin and pro-
-gastrin [35,41], which are not recognized by these
antisera and this explains the limited success of ga-
strimmune in treatment of these cancers. It is of in-
terest that glycine-extended gastrin and progastrin
exhibit a powerful tumor cell growth stimulatory
activity without affecting gastric acid stimulatory
action characteristic for G-17 [35,41].
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Figure 6. Schematic presentation of the proposal of important role of gastrin and H. pylori infection in gastric cancerogenesis (A). The eradication of
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Figure 7. The important role of gastrin in gastric cancerogenesis (see text).
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As mentioned before, in addition to gastrin, several
other growth factors are generated by tumor cells
and contribute to the stimulation of cancer cells via
specific growth factor receptors such as EGF-R [20].
The antisera against the membrane receptors for
EGF receptors (EGF-R) such as Herceptin (Genen-
tech, USA), that block these receptors at the breast
cancer cells, have been tried with some success
[42]. The most effective was found an anti-growth
agent, Glivec (Novartis, Germany), which cured
myelogenous leukemia [43] and some stromal ga-
stric tumors [44] blocking the intracellular signal
pathways of growth factors. Various endocrine tu-
mors such s gastrinoma can be successfully treated
using octreotide (Novartis) that binds specific so-
matostatin-receptors (SST2-R), that are regularly
present on the normal G-cells but also on the ga-
strin-producing cancer cells [45]. Many other anti-
-growth factors (e.g. IMC-C225 – Memorial Sloan
Kettering) and anti-gastrin agents are now under
active laboratory or clinical trials though they are
not expected to kill the cancerous cells but only to
reduce or abolish their growth or to augment the
anticancer efficacy of classic chemotherapy. Only
Glevec has been approved by FDA for the treat-
ment of chronic myelogenous leukemia [43].
Apoptosis, angiogenesis ans COX-2 expression
Recent studies have shown that the H. pylori infec-
tion first enhances both apoptosis (A) and mucosal
cell proliferation (P) but shen chronic active gastri-
tis becomes atrophic with intestinal metaplasia and
dysplasia it disturbes balance between cell survival
and (apoptosis) resulting in the dysregulation of the
genes controlling the apoptosis that may be closely
related to the cancer development (Fig. 9). The
Bcl-2 family of proteins has been shown to be in-
volved in the inhibition of the apoptosis [20,46,
47]. Some other members of this family of prote-
ins, such as Bax, are promotors of apoptosis [47].
There is an evidence that tumor development is as-
sociated with the inactivation of Bax and with the
over-expression of Bcl-2, leading to an overall inhi-
bition of apoptosis [47]. The expression of apopto-
sis-related genes bax and bcl-2 have been studied
in various types of cancers but their relationship to
growth factors, especially to gastrin, HGF, TGF and
gastrin, have not been thoroughly examined in ga-
stric cancer tissue, cancer margin or intact normal
mucosa.
According to our experience, Bcl-2, unlike Bax,
which was detected only in about 56% of GC, but
has been found in all cancer samples (100%), in
80% of cancer margin and in 64% of normal tissue
samples. The bcl-2 expression in GC was higher
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than that of bax, and the calculated bax/bcl-2 ratio
was several times lower in the cancer than in can-
cer margin or in adjacent normal mucosa (Fig. 10).
Unlike the intact gastric mucosa, in which no pro-
tein expression for HGF and Bax was found and
Bcl-2 was only weakly expressed, the biopsy speci-
men taken from gastric cancer, showed increased
expression of HGF and TGFα in about 35% of ca-
ses. In summary, we found that patients infected
with H. pylori - CagA-positive strains, are at a hi-
gher risk of developing GC. We also confirmed
that the increased production of gastrin [19] and
the over-expression of growth factors such as HGF
and TGFα [48, 49] contribute to gastric carcinoge-
nesis. Finally, in GC, the dysregulation of the
Bax/Bcl-2 system was noticed with a significant
down-regulation of proapoptotic Bax.
Cancerogenesis results from uncontrolled cell proli-
feration and an increase in the number of cells
with mutated genes with genome instability and
the appearance of cell subpopulation with altered
chromosomes. Initially the tumor growth may be
local so called carcinoma in situ but then the neo-
plastic cells loose their contact with basal membra-
ne (due to activity of collagenase IV) and infiltrate
the neighboring tissues. This uncontrolled cell pro-
liferation is accompanied by the inhibition of
apoptosis, which normally is the only way of remo-
val of damaged or unnecessary cells. Several proto-
oncogenes participate in this process such as C-
-Myc stimulating both apoptosis and cell prolifera-
tion, p53 that normally serves as genome guardian
and repairs DNA but when mutated it stops to re-
pair DNA resulting in the inhibition of apoptosis
and increase in cell survival and in effect in incre-
ase of tumor size.
Scheme proposing a key role of gastrin in gastric
cancerogenesis is presented on Fig. 7. Point muta-
tion of K-ras which can occur randomly in gastric
mucosa exposed to the influence of H. pylori and
its products lead to cascade of events. Oncogenic
mutation occurring in K-ras results in its elevated
intracellular activity causing overexpression of ga-
strin and other growth factors like TGFα, HGF and
EGF [50,51]. Furthermore cytotoxic products of H.
pylori evoke activation of NF-κ-B-dependent cyto-
kines IL-8, TNFα [52,53]. Elevated level of those
cytokines adds to overexpression of gastrin gene.
Gastrin as a potent mitogen using MAP-kinases and
C-jun amino-terminal kinase signal transduction
pathway promotes growth and cell division depen-
dent on c-fos and c-jun activity [54,55]. Moreover,
gastrin is able to activate p53 gene expression wi-
thout activation of cell cycle inhibitors (p21) [56].
This can lead to cell cycle dysregulation which with
already activated mitogenic activity can result in
Figure 11. Expression of COX-1 and COX-2 in MALT-lymphoma, antrum and corpus of stomach before and after H. pylori eradication.
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abnormal hyperproliferation of epithelial cells and
finally gastric cancer formation.
Tumor growth (steps 3 in cancerogenesis) that re-
sults from the proliferation of cancerous cells requ-
ires increased supply of nutrients and oxygen thro-
ugh the excessive growth of new vessels in tumor –
angiogenesis (step 4 in cancerogenesis). This pro-
cess is determined mainly by the induction of COX-
-2, a rate-limiting enzyme in prostaglandin (PG) bio-
synthesis [57,58], possibly due to the action of po-
tent mitogens such as gastrin and growth factor
(TGFα, HGF) generated in the tumor tissue [19,20,
35,59,60]. COX-2 in turn stimulates the release of
PG and angiogenic substances such as VEGF, bFGF,
and angiopoetins. Such overexpression of COX-2
has been detected in the H. pylori infected gastric
mucosa and this was further enhanced in the tumor
tissue [57–59]. After eradication of H. pylori, the
expression of COX-2 disappeared from previous si-
te of MALT tumor and significantly fell in infected
antrum and corpus mucosa (Fig. 11). Following pre-
treatment with Vioxx and inhibition of COX-2, the
expression of this enzyme was enhanced, thus rein-
forcing the suggestion that the selective inhibition of
COX-2 may provide a chemopreventive effect aga-
inst gastric cancerogenesis [60].
The treatment at the step 3 of cancerogenesis inc-
ludes the administration of specific COX-2 blockers
(such as Vioxx or Celecoxib) that are expected to
reduce the angiogenesis, resulting in the attenu-
ation of tumor growth.
Association of H. pylori andf MALT-lymphoma.
Involvement of gastrin and cyclooxygenase-2
Gastric lymphomas are the commonest of the extra-
nodal lymphomas but they comprise less than 5% of
all gastric cancers [60]. The gastric lymphoma show
characteristic features closely related to the structure
and function of gastric mucosa so called MALT (Mu-
cosa Associated Lymphoid Tissue) and appear to be
evolved to protect the mucosa directly exposed to
antigens in gastric environment such as the presence
of H. pylori (Fig. 12). Normally there is no lymphoid
tissue in the stomach, but the appearance of such
Figure 12. Typical endoscopic, endosonographic and histolkogical pictures in MALT-lymphoma patients used in our study [20,60].
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follicules in the gastric mucosa is virtually pathogno-
monic to H. pylori infection (Fig. 13).
There are several independent sources of evidence
that link prior H. pylori infection with MALT-lym-
phoma [60–66] including; 1. The presence of H.
pylori can be detected in more than 90% of cases
of MALT-lymphoma (Fig. 14); 2) Eradication of H.
pylori leads to the resolution of low-grade MALT
lymphoma with over 70% of cases in stage IE of
MALT-lymphoma regressing almost completely fol-
lowing successful anti-H. pylori therapy (Fig. 15); 3)
despite of the composition of the MALT-lymphoma
tumors consisting predominantly with B lymphocy-
tes, a marked increase of gastrin has been noticed
both in the gastric lumen and the plasma similar to
that observed in H. pylori infected GC patients and
accompanied by the marked increment in plasma
levels of cytokines (IL-1, IL-8 and TNFα) that could
contribute to the stimulation of gastrin release; 4.
The source of this gastrin has not been fully establi-
shed but the fact that the lymphoma tissue conta-
ined several times higher level of gastrin than the
intact gastric mucosa and the finding of the detec-
tion of gene expression in this tissue of both gastrin
receptors (CCKB) and gastrin itself is in keeping
with our hypothesis that the lymphocytes B overe-
xpress gastrin and its receptors that are involved in
the MALT-lymphoma growth. Our in vitro studies
with lymphoblasts support the overall role of ga-
strin and cytokines in the pathogenesis of MALT-
-lymphoma.
Fig. 16 shows schematically the proposed patho-
mechanism of MALT-lymphoma based on our fin-
dings obtained from the limphoid cells emphasi-
zing central role of gastrin in its development. In H.
pylori infected stomach several processes including
apoptosis, hyperproliferation of epithelial cells and
infiltration of macrophages (Mf) and monocytes
(Mo) can occur. Elevation of gastrin (presumably
originating from the lymphocytes) during infection
as well as an increased expression and synthesis of
proinflammatory and chemoatractive cytokines (IL-
-1, IL-6, IL-7, IL-8, IL-15) evoke local immune re-
sponse and clonal activation of T lymphocytes
(LyT) sensitized by specialized antigen presenting
cells (APC), followed by B cells (LyB) activation and
Figure 13. Schematic presentation of development of lymphoid follicles and MALT lymphoma in H. pylori infected stomach (Genta et al, 2000).
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excessive proliferation. In this model MALT lym-
phoma formation can be considered as an abnor-
mal immune response to H. pylori infection. Ga-
strin acts as a trophic hormon not only for gastric
mucosa but also for B lymphocytes excessively pro-
liferating from lymphoid follicle and penetrating
gastric mucosa.
The possibility of cure of gastric MALT-lymphoma
using an anti-H. pylori therapy is an excellent
example of the susceptibility of the H. pylori -indu-
ced gastric tumor (as well as gastroduodenal ulce-
ration) to the treatment and cure by eradication of
the germ from the stomach (Fig. 17). Although
Genta et al. [64] showed that the eradication of H.
pylori is followed by reduced, although not com-
plete disappearance of lymphoid follicles in the ga-
stric mucosa, the data obtained from various onco-
logy centers provide strong circumstantial evidence
in support of the pathological role played by H. py-
lori infection in the pathogenesis of gastric MALT-
-lymphoma and has led to inclusion of this tumors
as an indication for treatment in all H. pylori Con-
sensus Conferences held to date in USA or Europe
[65,66]. Figure 17 illustrates that dominant feature
of H. pylori infection is greatly enhanced plasma
gastrin level, independent on the intragastric pH.
These secretory disorders may result either in du-
odenal ulcer when infection dominates in antrum
or gastric ulcer, MALT-lymphoma or cancer when
infection is confined to the corpus mucosa.
It is of interest that MALT-lymphoma, similarly to
adenocarcinoma, expresses COX-2 and generates
excessive amounts of PG that could be responsible
Figure 14. Seroprevalence of H. pylori IgG and Cag A in MALT-lymphoma (on left) and the endoscopic picture of MALT-lymphoma tumor (on right).
Figure 15. H. pylori eradication therapy leads to almost complete
regression of MALT lymphoma tumors.
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for the lymphocyte B proliferation, the decrease in
apoptosis, the mutagenesis and the angiogenesis.
Following the H. pylori eradication, there was not
only the regression of the tumor but also an imme-
diate fall in gastrin release followed by reduction in
COX-2 expression. Thus, similar molecular changes
appear to operate in MALT-lymphoma as in GC,
indicating that there is a common pathomecha-
nism underlying the apparently different disorders,
gastric cancerogenesis and the MALT-lymphoma
[67].
CONCLUSIONS
1. The infection with H. pylori, especially expres-
sing CagA, is significantly higher in gastric cancer
and occurs in almost all MALT-lymphoma pa-
tients, playing a crucial role in gastric canceroge-
nesis;
2. The major morphological events in gastric can-
cerogenesis is the development of atrophic ga-
stritis passing in cascade to intestinal metaplasia
and dysplasia followed by the transformation of
normal mucosal cells into malignant cells, at first
developing locally but then infiltrating neighbo-
ring tissues and finally spreading via blood or
lymph vessels to lymph nodes and distant or-
gans.
3. MALT-lymphoma shows different morphological
feature with predominant formation of lymphoid
follicules in the mucosa and then excessively in-
filtration and destruction of the surface epithe-
lium followed by slow infiltration of neighboring
tissues and lymphnodes;
4. The molecular pathomechanism of gastric ade-
nocarcinoma and MALT-lymphoma basically has
common features including an upregulation of
gastrin and its receptors, that in combination
with other growth factors (HGF, TGFα and EGF)
seem to act as cancerogens, playing a crucial ro-
le in the transformation of normal mucosal cells
Figure 16. Schematic presentation of pathomechanism of H. pylori induced MALT-lymphoma with central role of gastrin and growth factors.
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or lymphocytes into the malignant cells through the
mutation of several protooncogenes such as C-
-myc, K-ras, C-fos etc. that are responsible for the
increased proliferation and spreading of these cells;
5. Both gastric cancer and MALT-lymphoma show
overexpression of COX-2 probably induced by
gastrin and other growth factors and appear to
contribute to angiogenesis in growing tumor via
production of PG, bFGF, VEGF, angiopoetins
etc.
6. The major difference between gastric adenocar-
cinoma and MALT-lymphoma is that eradication
of H. pylori causes almost complete regression
and cure of MALT lymphoma, whereas such
eradication in gastric cancer, though recommen-
ded, is probably successful only in precancerous
state but not in fully developed cancer.
7. Based of the results of these studies we postulate
the nation-wide periodic screening of patients,
especially closest family members of gastric can-
cer patients or those showing history of gastrec-
tomy, repeated gastric ulcer or chronic atrophic
gastritis.
8. The research on uncontrolled growth and proli-
feration of cancer cells emphasizes the impor-
tant role of growth factors, their receptors at the
cancer cell membrane and intracellular enzyma-
tic pathways. The preliminary results with anti-
growth agents inactivating the growth factors,
their receptors, intracellular signaling systems or
the angiogenesis seem to be the most promising
anti-cancer remedies.
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